Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 2,755,099 |
|
|||||
| News | - | ||||||
| Day High | 18.37 | Low High |
|||||
| Day Low | 17.51 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| TG Therapeutics Inc | TGTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.77 | 4.45% | 18.09 | 14:02:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 17.51 | 17.51 | 18.37 | 17.32 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 21,328 | 2,755,099 | $ 18.07 | $ 49,790,678 | - | 6.46 - 31.92 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:02:48 | 10 | $ 18.095 | USD |
TG Therapeutics (TGTX) Options Flow Summary
TG Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.79B | 154.42M | - | 233.66M | 12.67M | 0.08 | 219.98 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TG Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TGTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.50 | 18.37 | 16.42 | 17.09 | 3,596,505 | 1.59 | 9.64% |
| 1 Month | 13.98 | 18.37 | 12.93 | 15.41 | 4,426,084 | 4.11 | 29.40% |
| 3 Months | 13.75 | 19.0175 | 12.84 | 15.58 | 3,791,615 | 4.34 | 31.56% |
| 6 Months | 10.83 | 22.67 | 10.4212 | 15.81 | 4,479,749 | 7.26 | 67.04% |
| 1 Year | 30.90 | 31.92 | 6.46 | 14.84 | 4,748,149 | -12.81 | -41.46% |
| 3 Years | 34.30 | 41.00 | 3.48 | 14.45 | 3,532,694 | -16.21 | -47.26% |
| 5 Years | 6.95 | 56.74 | 3.48 | 16.37 | 2,807,777 | 11.14 | 160.29% |
TG Therapeutics Description
| TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. |
